



Press Release

October 26, 2010

Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531
NSE: STAR

Strides' Generic Oseltamivir Receives WHO Prequalification for treatment of H1N1

*Only the second company globally to receive WHO prequalification for
Generic Oseltamivir*


Strides Arcolab, a leading Indian pharmaceutical company, today announced that the World Health Organization (WHO) has prequalified Strides' generic version of Oseltamivir – capsules 75mg for the treatment of H1N1 infection. **Strides thus becomes only the second company globally to receive WHO pre-qualification for generic Oseltamivir.**

Oseltamivir is manufactured at Strides' USFDA approved and WHO pre-qualified oral dosage forms manufacturing facility in Bangalore.

The mission of the 'Prequalification Programme', a United Nations initiative managed by WHO, is to make good quality medicines available for everyone. Prequalification of medicinal products normally involves evaluation of data relating to their quality, safety and efficacy as well as inspection of the relevant manufacturing and clinical site. The list of prequalified medicinal products is used principally by United Nations agencies including UNAIDS and UNICEF to guide their procurement decisions.

Strides commenced supply of Oseltamivir in 2009 and is an approved supplier to the Ministry of Health, Government of India besides exporting Oseltamivir capsules to other countries. The product is also available in the Indian retail market under the brand name 'STARFLU'.

Strides continues to keep itself in readiness to supply at least 1.5 million treatments, should any global emergency arises.



About Strides Arcolab Limited:

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company's website at www.stridesarco.com.

For further information, please contact:

Aloka Sengupta President – Business Development (India Ops) Ph: +91 80 6658 0748	Mr. Mahesh Nair, Corporate Voice/ Weber Shandwick Mobile : +91 98803 76648 Email: maheshn@corvoshandwick.co.in
Mr. N Kannan (Investor Relations) Tel : +91 98450 54745	Ms. Kasturi Wasmatar, Corporate Voice/ Weber Shandwick Mobile: 99167 28393 Email: kasturi@corvoshandwick.co.in
Ms. Melissa Arulappan (Media) Tel: +91 98450 22389	

